Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial

By sjmartinez • April 1, 2023

Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Eganelisib, a First-in-Class PI3K-γ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial. Clin Cancer Res. 2023 Mar 31:CCR-22-3313. doi: 10.1158/1078-0432.CCR-22-3313. Epub ahead of print. PMID: 37000164.

Tags: Hematology/Oncology, Publications

Transcriptional profiling clarifies a program of enzalutamide extreme non-response in lethal prostate cancer

Kumaraswamy A, Hu YM, Yates JA, Zhang C, Rodansky E, Khokhani D, Flores D, Duan Z, Zhang Y, Tabatabaei S, Slottke R, Ye S, Lara[...]

Predicting subjective sleepiness during auditory cognitive testing using voice signaling analysis

Te TT, Boland MR, Ghadimi S, Dzierzewski JM, Alessi C, Martin JL, Kremen S, Bui AAT, Naeim A, Fung CH. Predicting subjective sleepiness during auditory[...]

Feasibility of cognitive testing and ecological momentary assessments using smartphones in middle aged and older adults with insomnia

Ghadimi S, Ereso J, Kaula AJ, Taptiklis N, Cormack F, Alessi C, Martin JL, Dzierzewski JM, Naeim A, Kremen S, Te T, Fung CH. Feasibility[...]